GRAIL Inc (GRAL) eyes early 2027 FDA approval for Galleri after a favorable advisory committee vote, even as revenue growth slows and losses widen.
Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.
GRAIL (GRAL) has an average rating of overweight and mean price target of $134.30, according to anal
Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.
The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.
Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works. The test is awaiting a final decision by the FDA.
Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.
An FDA panel discussed the company's blood screening test for cancer.
This is the newest page. Registered accounts read further back.